White Mark Andrew
Known title: Chief Medical OfficerCIK: 0001973240
Associated companies
Transaction History
| RCKT | ▼ Sell | Open Market | 3,080 | $51K | 10/31/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 3,026 | $62K | 7/8/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 12,532 | $309K | 4/8/2024 | View on chart |
| RCKT | ▲ Buy | Grant | 11,096 | $0 | 2/16/2024 | View on chart |
| RCKT | ▲ Buy | Grant | 76,662 | $0 | 4/4/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial
Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial. Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.